# The Present and Future of Pain Management in Patients With Chronic Kidney Disease: A Narrative Review

**Authors:** Igor Wilderman, Francesca Sarzetto, Budvin Wijetillake, Sydney Verdun

PMC · DOI: 10.7759/cureus.100490 · Cureus · 2025-12-31

## TL;DR

This review discusses the challenges and current strategies for managing chronic pain in patients with kidney disease, emphasizing the need for personalized and cautious treatment.

## Contribution

The paper provides a comprehensive overview of both current and emerging pain management approaches tailored for patients with chronic kidney disease.

## Key findings

- Chronic pain in CKD patients is often nociceptive or neuropathic and requires careful drug dosing due to altered metabolism and excretion.
- Pharmacological approaches and emerging alternatives like cannabinoids and low-dose naltrexone are reviewed for their potential in pain management.
- Individualized treatment plans and close monitoring are essential to balance efficacy and safety in CKD patients.

## Abstract

Chronic kidney disease (CKD) is an increasingly common ailment, greatly affecting the quality of life, morbidity, and mortality of the population. In addition, more than half of patients with CKD experience chronic pain, mostly of nociceptive or neuropathic origin, and physicians frequently have to find a difficult balance between safety and efficacy to control it. The altered metabolism and renal excretion in patients with CKD modify the pharmacokinetics and pharmacodynamics of several analgesic drugs, making this population more prone to side effects and lower efficacy, since the doses often need to be reduced. This narrative review describes the current pharmacological approaches for nociceptive and neuropathic pain, and emerging alternatives, such as cannabinoids and low-dose naltrexone. We also describe the current knowledge on anesthesia, perioperative and acute pain management, and injectables, including ketamine and corticosteroids (intra-articular and epidural). In the variable and possibly deteriorating clinical context of CKD, this review shows that pain management needs to be individualized and carefully discussed with the patient; close monitoring is also necessary to adjust the treatment and obtain effective pain control while minimizing the risk.

## Linked entities

- **Chemicals:** cannabinoids (PubChem CID 9852188), ketamine (PubChem CID 3821)
- **Diseases:** chronic kidney disease (MONDO:0005300)

## Full-text entities

- **Diseases:** neuropathic (MESH:D009437), chronic pain (MESH:D059350), Pain (MESH:D010146), CKD (MESH:D051436)
- **Chemicals:** cannabinoids (MESH:D002186), ketamine (-), naltrexone (MESH:D009271)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12857586/full.md

## Figures

4 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12857586/full.md

## References

91 references — full list in the complete paper: https://tomesphere.com/paper/PMC12857586/full.md

---
Source: https://tomesphere.com/paper/PMC12857586